Menu
Recruiting NCT06155643

EKO SENSORA: Detecting Clinically Significant Murmurs

No phase Interventional Heart Murmurs

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Eko Sensora.
Who it may be relevant to
Registry conditions: Heart Murmurs. Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
United States
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Overview

The Eko Artificial Intelligence (AI) has primarily been evaluated in the primary care setting. The digital stethoscope records a phonocardiogram of heart sounds of the patient and uses machine learning artificial intelligence to identify if there are abnormalities present (Eko Health, 2023). The Eko SENSORA will be tested in the emergency department. Chest pain, fatigue, shortness of breath and syncope are all symptoms that could indicate a cardiac dysfunction. The hypothesis is that this device will allow us increased ability to detect valvular heart disease that is clinically significant.

Interventions

  • Device Eko Sensora
    The exam involves placing the stethoscope in the aortic, pulmonic, tricuspid, and mitral areas for 15-30 seconds until a green light is displayed indicating that useful sound has been recorded. The recording is then uploaded by the device using wi-fi to the AI program for analysis. It does not carry patient identifiers. The device then indicates whether a clinically significant heart murmur was heard, and if so in which recording.

Primary outcome measures

  • Number of new clinically significant heart murmurs detected [Time frame: through study completion, an average of 90 days]
Secondary outcome measures (1)
  • Number of echocardiograms ordered [Time frame: through study completion, an average of 90 days]

Eligibility criteria

Inclusion criteria

  • Chief complaint of chest pain, shortness of breath, difficulty breathing, or syncope/near-syncope.
  • Patients with chief complaint of Weakness would be eligible if over the age of 50 and have a history of at least two of hypertension, BMI>/= 30, diabetes, hyperlipidemia, atrial fibrillation, heart attack, stroke/Transient ischemic attack, prior cardiac surgery or angiography

Exclusion criteria

  • Contact isolation patients
  • Pediatric patients under the age of 18

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
N/A
Model
Single group
Masking
Open label
Primary purpose
Screening

Study locations

United States · 1 center
  • Corewell Health Lakeland — Saint Joseph

Identifiers

NCT: NCT06155643 · 1635

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗